The Fast Track designation significantly de-risks CTIM-76's development path and could accelerate its route to market. Traders should monitor the upcoming interim data readout in June 2026, as positive results could further boost the stock. This regulatory milestone enhances the company's pipeline value and may attract partnership interest.
Price Chart
Executive Summary
Context Therapeutics Inc. (CNTX) announced that the FDA has granted Fast Track designation to its investigational drug CTIM-76 for the treatment of platinum-resistant ovarian cancer. This designation highlights the drug's potential to address an unmet medical need and may expedite its development and review. The company also noted that interim data from the Phase 1a trial is expected in June 2026.
Key Facts
- FDA grants Fast Track designation to CTIM-76 for platinum-resistant ovarian cancer
- Fast Track designation aims to expedite development and review of drugs for serious conditions
- Interim data from Phase 1a trial expected in June 2026
- CTIM-76 is a Claudin 6 x CD3 T cell engaging bispecific antibody
- Drug targets patients who have received all standard of care therapies
Financial Impact
Potential to accelerate development timeline and increase drug's commercial value
Risk Factors
- Interim data in June 2026 may not meet expectations
- Fast Track designation does not guarantee eventual FDA approval
- Clinical trial may encounter safety or efficacy issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-022931 |
| Document: a04022026fasttrackdesignat.htm | 0001628280-26-022931 |
| Document: 0001628280-26-022931-index-headers.html | 0001628280-26-022931 |
| Document: 0001628280-26-022931-index.html | 0001628280-26-022931 |
| Document: 0001628280-26-022931.txt | 0001628280-26-022931 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 15, 2026 19w ago | 8-K | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2347 (−65.44%) |
Jun 15, 2026 19w ago | Press Release | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2347 (−65.44%) |
May 18, 2026 23w ago | PRESS-RELEASE / 8-K | $2.15 $2.63 | ▲ +22.33% | ▲ +20.71% | $0.2347 (−89.08%) |
May 6, 2026 24w ago | Press Release | $2.33 $2.36 | ▲ +1.29% | ▼ −0.22% | $0.2347 (−89.93%) |
May 1, 2026 25w ago | 8-K | $2.30 $2.39 | ▲ +3.91% | ▲ +0.98% | $0.2347 (−89.80%) |
Apr 2, 2026 29w ago | 8-K | $2.72 $2.49 | ▼ −8.46% | ▼ −12.07% | $0.2347 (−91.37%) |
Mar 23, 2026 31w ago | Press Release | $3.18 $2.62 | ▼ −17.61% | ▼ −17.19% | $0.2347 (−92.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers